Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV-Reference-Cited by-同舟云学术

Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV

Published:2024-03-19 Issue:8 Volume:35 Page:651-653
ISSN:0956-4624
Container-title:International Journal of STD & AIDS
language:en
Short-container-title:Int J STD AIDS

Author:

Harrison Iris¹^ORCID,DeSear Kathryn²,Santevecchi Barbara A³,Venugopalan Veena³,Cherabuddi Kartikeya⁴,Iovine Nicole⁴,Radhakrishnan Nila⁵

Affiliation:

1. University of Florida College of Medicine, Gainesville, FL, USA

2. Department of Pharmacy, University of Florida Health, Gainesville, FL, USA

3. Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USA

4. Division of Infectious Diseases & Global Medicine, University of Florida Health, Gainesville, FL, USA

5. Department of Medicine, University of Florida Health, Gainesville, FL, USA

Abstract

A man with advanced HIV presented with verrucous plaques 2-3 months after initial mpox infection. He received two courses of tecovirimat without resolution of initial mpox lesions and development of new lesions raising concern for resistance. He was treated with two doses of brincidofovir and demonstrated improvement 6 months later.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/09564624241238813

Reference8 articles.

1. Antivirals With Activity Against Mpox: A Clinically Oriented Review

2. Not only monkeypox infection: Keratoderma blenorrhagicum

3. Mpox in people with past infection or a complete vaccination course: a global case series

4. Hypertrophic verrucous lesions after monkeypox virus infection

5. Mpox in people with advanced HIV infection: a global case series